Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024
Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in the UBS Virtual Opthalmology Day 2024. The event will feature a fireside chat with Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular, scheduled for Wednesday, October 2, 2024, at 3:00 PM ET.
The company, which focuses on developing innovative therapies for retinal diseases and other eye conditions, will also host investor meetings during the conference. Interested parties can access a live webcast of the fireside chat through the Investors section of Ocular's website at investors.ocutx.com.
This participation underscores Ocular Therapeutix's commitment to engaging with the investment community and sharing insights about its efforts to improve vision through advanced therapeutics.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato la sua partecipazione al UBS Virtual Ophthalmology Day 2024. L'evento prevede un colloquio informale con Pravin U. Dugel, MD, Presidente Esecutivo, Presidente e CEO di Ocular, programmato per mercoledì 2 ottobre 2024, alle 15:00 ET.
L'azienda, che si concentra sullo sviluppo di terapie innovative per le malattie retiniche e altre patologie oculari, ospiterà anche incontri con gli investitori durante la conferenza. Le parti interessate possono accedere a una trasmissione in diretta del colloquio informale attraverso la sezione Investitori del sito web di Ocular all'indirizzo investors.ocutx.com.
Questa partecipazione sottolinea l'impegno di Ocular Therapeutix a coinvolgere la comunità degli investitori e a condividere informazioni sui suoi sforzi per migliorare la visione attraverso terapie avanzate.
Ocular Therapeutix (NASDAQ: OCUL) ha anunciado su participación en el Día Virtual de Oftalmología de UBS 2024. El evento incluirá una charla informal con Pravin U. Dugel, MD, Presidente Ejecutivo y Director General de Ocular, programada para miércoles, 2 de octubre de 2024, a las 3:00 PM ET.
La compañía, que se enfoca en desarrollar terapias innovadoras para enfermedades de la retina y otras afecciones oculares, también organizará reuniones con inversores durante la conferencia. Las partes interesadas pueden acceder a una transmisión en vivo de la charla informal a través de la sección para inversores en el sitio web de Ocular en investors.ocutx.com.
Esta participación subraya el compromiso de Ocular Therapeutix con el involucramiento de la comunidad inversora y la compartición de información sobre sus esfuerzos por mejorar la visión mediante terapias avanzadas.
Ocular Therapeutix (NASDAQ: OCUL)는 UBS 가상 안과의 날 2024에 참여한다고 발표했습니다. 이 이벤트는 Pravin U. Dugel, MD, Ocular의 이사장, 사장 및 CEO와의 격의 없는 대화가 포함되며, 2024년 10월 2일 수요일, 오후 3:00 ET로 예정되어 있습니다.
망막 질환 및 기타 안과 질환에 대한 혁신적인 치료법 개발에 집중하는 이 회사는 컨퍼런스 기간 동안 투자자 미팅도 주최할 것입니다. 관심 있는 분들은 Ocular 웹사이트의 투자자 섹션에서 격의 없는 대화의 실시간 웹캐스트에 접근할 수 있습니다. 주소는 investors.ocutx.com입니다.
이번 참여는 Ocular Therapeutix가 투자자 커뮤니티와 소통하고 최신 치료법을 통해 시력을 개선하려는 노력을 공유하려는 의지를 강조합니다.
Ocular Therapeutix (NASDAQ: OCUL) a annoncé sa participation à la Journée Virtuelle d'Ophthalmologie de UBS 2024. L'événement comprendra une discussion informelle avec Pravin U. Dugel, MD, Président Exécutif et PDG d'Ocular, prévue pour mercredi 2 octobre 2024, à 15h00 ET.
L'entreprise, qui se concentre sur le développement de thérapies innovantes pour les maladies de la rétine et d'autres conditions oculaires, organisera également des réunions avec des investisseurs durant la conférence. Les parties intéressées peuvent accéder à une diffusion en direct de la discussion informelle via la section Investisseurs du site web d'Ocular à l'adresse investors.ocutx.com.
Cette participation souligne l'engagement d'Ocular Therapeutix à interagir avec la communauté des investisseurs et à partager des insights sur ses efforts pour améliorer la vision grâce à des thérapies avancées.
Ocular Therapeutix (NASDAQ: OCUL) hat seine Teilnahme am UBS Virtual Ophthalmology Day 2024 angekündigt. Die Veranstaltung umfasst ein informelles Gespräch mit Pravin U. Dugel, MD, dem Vorstandsvorsitzenden, Präsidenten und CEO von Ocular, das für Mittwoch, den 2. Oktober 2024, um 15:00 Uhr ET angesetzt ist.
Das Unternehmen, das sich auf die Entwicklung innovativer Therapien für Netzhauterkrankungen und andere Augenkrankheiten konzentriert, wird während der Konferenz auch Treffen mit Investoren veranstalten. Interessierte Parteien können über den Bereich Investoren auf der Website von Ocular unter investors.ocutx.com auf einen Live-Stream des informellen Gesprächs zugreifen.
Diese Teilnahme unterstreicht das Engagement von Ocular Therapeutix, mit der Investment-Community in Kontakt zu treten und Einblicke in seine Bemühungen zur Verbesserung des Sehvermögens durch fortschrittliche Therapien zu teilen.
- None.
- None.
BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in the UBS Virtual Opthalmology Day 2024:
UBS Virtual Opthalmology Day 2024
Fireside Chat Date: Wednesday, October 2, 2024
Presentation Time: 3:00 PM ET
Ocular Presenter: Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer
Location: Virtual
In addition to the fireside chat, Ocular leadership will host investor meetings at the conference. A live webcast of the fireside chat can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When is Ocular Therapeutix (OCUL) presenting at the UBS Virtual Opthalmology Day 2024?
Who will be representing Ocular Therapeutix (OCUL) at the UBS Virtual Opthalmology Day 2024?
How can investors access Ocular Therapeutix's (OCUL) presentation at the UBS Virtual Opthalmology Day 2024?
What type of event will Ocular Therapeutix (OCUL) participate in at the UBS Virtual Opthalmology Day 2024?
